The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Key stereotype subsets of BcR immunoglobulin associated with worse outcomes in CLL
Andreas Agathangelidis, PhD, Center for Research and Technology Hellas, Thermi, Greece, discusses key stereotype subsets of B-cell receptor (BcR) immunoglobulin in chronic lymphocytic leukemia (CLL). He identifies two key subsets, subset two and subset eight, which are associated with more aggressive disease and increased risk of Richter’s transformation. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
